

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

**Title:** Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.

**Short title:** Predictors of severe or lethal COVID-19.

**Authors:** Francesca Bravi <sup>1¶</sup>; Maria Elena Flacco <sup>2¶</sup>; Tiziano Carradori <sup>1</sup>; Carlo Alberto Volta, <sup>1,3</sup>; Giuseppe Cosenza <sup>4</sup>; Aldo De Togni <sup>4</sup>; Cecilia Acuti Martellucci <sup>5</sup>; Giustino Parruti <sup>6</sup>; Lorenzo Mantovani <sup>7</sup>; Lamberto Manzoli <sup>1,2\*</sup>.

**Affiliations:**

<sup>1</sup> "Sant'Anna" University Hospital of Ferrara, Italy;

<sup>2</sup> Department of Medical Sciences, University of Ferrara, Italy;

<sup>3</sup> Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Italy;

<sup>4</sup> Local Health Authority of Ferrara, Italy;

<sup>5</sup> Department of Biomedical Sciences and Public Health, University of the Marche Region, Ancona, Italy;

<sup>6</sup> Local Health Authority of Pescara, Italy;

<sup>7</sup> School of Medicine and Surgery, University Bicocca, Milan, Italy.

<sup>¶</sup> These authors equally contributed to the present work.

\* Corresponding author

Email: lmanzoli@post.harvard.edu (La.M.)

## 25 **Abstract**

26 **Aims:** This retrospective case-control study was aimed at identifying potential independent predictors of  
27 severe/lethal COVID-19, including the treatment with Angiotensin-Converting Enzyme inhibitors (ACEi)  
28 and/or Angiotensin II Receptor Blockers (ARBs).

29 **Methods and Results:** All adults with SARS-CoV-2 infection in two Italian provinces were followed for a  
30 median of 24 days. ARBs and/or ACEi treatments, and hypertension, diabetes, cancer, COPD, renal and  
31 major cardiovascular diseases (CVD) were extracted from clinical charts and electronic health records, up to  
32 two years before infection. The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454  
33 (28.3%) had severe symptoms, 192 (12.0%) very severe or lethal disease (154 deaths; mean age 79.3 years;  
34 70.8% hypertensive, 42.2% with CVD). The youngest deceased person aged 44 years. Among hypertensive  
35 subjects (n=543), the proportion of those treated with ARBs or ACEi were 88.4%, 78.7% and 80.6% among  
36 patients with mild, severe and very severe/lethal disease, respectively. At multivariate analysis, no  
37 association was observed between therapy and disease severity (Adjusted OR for very severe/lethal COVID-  
38 19: 0.87; 95% CI: 0.50-1.49). Significant predictors of severe disease were older age (with AORs largely  
39 increasing after 70 years of age), male gender (AOR: 1.76; 1.40-2.23), diabetes (AOR: 1.52; 1.05-2.18),  
40 CVD (AOR: 1.88; 1.32-2.70) and COPD (1.88; 1.11-3.20). Only gender, age and diabetes also predicted  
41 very severe/lethal disease.

42 **Conclusion:** No association was found between COVID-19 severity and treatment with ARBs and/or ACEi,  
43 supporting the recommendation to continue medication for all patients unless otherwise advised by their  
44 physicians.

45

46 **Key words:** SARS-CoV-2; COVID-19; Angiotensin-converting enzyme inhibitors; Angiotensin II receptor  
47 blockers; case-control; Italy.

## 48 **Introduction**

49 Novel coronavirus disease (COVID-19) is spreading worldwide, and has caused over 250,000 deaths so far  
50 [1]. The mortality rate varies widely by age and across individuals, ranging from 0.2% among healthy,  
51 young-adults, to >10% among older persons with pre-existing conditions [1].

52 Although the pharmacological treatment was not assessed, the first observational studies on patients with  
53 severe disease reported a high prevalence of comorbidities that are often treated with angiotensin converting  
54 enzyme (ACE) inhibitors, such as cerebrovascular diseases, coronary heart disease, hypertension and  
55 diabetes [2-4]. Observing that human pathogenic coronaviruses bind their target cells through angiotensin-  
56 converting enzyme 2 (ACE2) [5], and that the expression of ACE2 is substantially increased in diabetics and  
57 patients who are treated with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs) [5, 6], Fang  
58 and colleagues hypothesized that the increased expression of ACE2 would facilitate infection with Severe  
59 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), thus the hypertension treatment with ACE2-  
60 stimulating drugs, as well as ACE2 polymorphisms, might increase the risk of developing severe COVID-19  
61 [7]. Consequently, this would lead to a serious conflict regarding treatment, because ACE2 reduces  
62 inflammation and has been suggested as a potential new therapy for inflammatory lung diseases, cancer,  
63 diabetes, and hypertension [7-11]. In the wake of two preliminary cohort studies reporting a lower [12] or  
64 similar [13] COVID-19 mortality among inpatients hypertensive subjects treated with ARBs and ACE  
65 inhibitors, the potential predictors of COVID-19 and of disease severity, including anti-hypertensive  
66 medications, were recently analyzed by three observational studies [14-16]. No increased risk emerged from  
67 the use of ARBs or ACE inhibitors; however, the role of other potentially linked predictors, including age  
68 and cardiovascular comorbidities [7, 17, 18], differed across the population analyzed, and still requires  
69 confirmation. We have performed a case-control study on all SARS-CoV-2 infected subjects diagnosed in  
70 two Italian provinces, retrieving admission and pharmacological data up to two years before infection, in  
71 order to confirm the potential independent predictors of severe/lethal COVID-19, including treatment with  
72 ACE inhibitors and/or ARBs.

73

74

## 75 **Materials and Methods**

76 This case-control, retrospective study compared the proportion of subjects treated with ARBs and/or ACE  
77 inhibitors among three groups of subjects with SARS-CoV-2 infection:

78 (a) asymptomatic infection or mild disease, defined as fever or malaise plus at least one of the followings:  
79 sore throat, muscle pain, shortness of breath, dry cough, headache, conjunctivitis, and diarrhea [19], with no  
80 hospital admission;

81 (b) severe disease, requiring hospital admission, not in an intensive care unit;

82 (c) very severe or lethal disease, requiring admission in an intensive care unit and/or causing death.

83 The sample includes all subjects with diagnosis of infection made in the Province of Ferrara, up to April 2,  
84 and the Province of Pescara, Italy, up to April 24, 2020, by the Central Laboratory of the University Hospital  
85 of Ferrara or the Central Laboratory of the Pescara Hospital (and confirmed by the National Institute of  
86 Health).

87 The data on background pharmacological treatment up to the previous two years (January 1, 2018) were  
88 obtained from the National database of drug prescription, and integrated with clinical chart information for  
89 hospitalized subjects. Data have been collected on the following drugs: ACE inhibitors (ATC classes: C09A  
90 and C09B), ARBs (C09C and C09D), and insulin or other anti-diabetic drugs (A10). Information on age,  
91 gender, and pre-existing conditions of all subjects were obtained through data-linkage with hospital  
92 discharge abstracts (Italian SDO), which have been queried from the day of the diagnosis until January 1st,  
93 2015. All admission data have been revised manually by two physicians (LM and MEF) and the following  
94 conditions have been included in the analyses: malignant tumors, major cardiovascular diseases (heart  
95 failure, myocardial infarction and stroke - CVD), type II diabetes, renal disease and chronic obstructive  
96 pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema).

97 The study complies with the Declaration of Helsinki, the research protocol was approved by the Ethics  
98 Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for  
99 informed consent was waived because of the retrospective and pseudo-anonymized nature of the data.

100 First, the differences across groups with mild, severe or very severe/lethal disease were evaluated using t-test  
101 (for continuous variables) and Mantel-Haenzsel chi-squared test for categorical ones. A sample restricted to  
102 hypertensive subjects was used to compare the subjects treated and untreated with ACE inhibitors or ARBs.

103 Multivariate logistic regression was used to investigate the potential independent predictors of severe or very  
104 severe/lethal COVID-19. Four models were built, two were restricted to hypertensive subjects (A and B),  
105 and two included the total sample (Models C and D) and. Models A and C were fit to predict severe or very  
106 severe disease (grouped together), while Models B and D to predict very severe/lethal disease only (and  
107 repeated to predict death, with similar results, which have not been shown to avoid redundancy). All  
108 recorded variables were included a priori in all models, with the exception of treatments with ACE inhibitors  
109 and ARBs, that were excluded from Models C and D because of multicollinearity with hypertension.  
110 Standard diagnostic procedures were adopted to check all models validity: influential observation analysis  
111 (Dbeta, change in Pearson chi-square and similar), multicollinearity, interaction terms, Hosmer-Lemeshow  
112 test for the goodness of fit and C statistic (area under the Receiving Operator Curve). Statistical significance  
113 was defined as a two-sided  $p$ -value $<0.05$ , and all analyses were carried out using Stata, version 13.1 (Stata  
114 Corp., College Station, TX, 2014).

115

## 116 **Results**

117 The sample consisted of 1603 subjects (mean age 58.0y; 47.3% males): 454 (28.3%) had severe symptoms,  
118 192 (12.0%) very severe or lethal disease (Table 1). 154 subjects deceased (mean age 79.3 years; 54.6%  
119 males); of them, 70.8% were hypertensive, 42.2% were diagnosed a CVD; 27.9% diabetics. Twenty subjects  
120 with very severe disease were younger than 60 years; the youngest being a male aged 33 years. Of those  
121 deceased, eight were younger than 60 years, and the youngest was a female aged 44 years.

122 At univariate analysis, as compared to the subjects with mild disease, those with severe or very severe/lethal  
123 disease were significantly more likely to be older, diabetics, hypertensive, diagnosed with COPD, CVD, and  
124 renal disease, and treated with ARBs and/or ACE inhibitors (all  $p<0.05$ ). Among hypertensive subjects  
125 ( $n=543$ ), however, the proportion of those treated with ARBs or ACE inhibitors were higher among those  
126 with asymptomatic/mild disease (88.4%, versus 78.7% and 80.6% among patients with severe and very  
127 severe/lethal disease, respectively - Table 1; Figure 1).

128

129 **Table 1. Characteristics of the sample.**

Variables	Overall sample (n=1603)	Mild (n=957)	Severe (n=454)	Very severe/lethal (n=192)	p <sup>A</sup>	p <sup>B</sup>	p <sup>C</sup>
Mean age in years (SD)	58.0 (20.9)	50.4 (20.2)	66.4 (16.9)	76.2 (12.9)	<0.001	<0.001	<0.001
Male gender, %	47.3	42.5	53.1	57.3	<0.001	<0.001	0.3
Diabetes, %	12.1	6.8	16.5	28.1	<0.001	<0.001	0.001
COPD, %	6.0	2.9	9.2	14.1	<0.001	<0.001	0.070
Cancer, %	7.6	5.1	10.1	14.1	<0.001	<0.001	0.2
Major cardiovascular diseases <sup>D</sup> , %	16.1	6.9	26.9	36.5	<0.001	<0.001	0.015
Renal disease, %	5.4	2.4	8.8	12.0	<0.001	<0.001	0.2
Hypertension, %	33.9	21.6	45.6	67.2	<0.001	<0.001	<0.001
Antihypertensive treatment with:							
- ACE inhibitors, %	15.7	11.2	19.4	29.2	<0.001	<0.001	0.006
- ARBs, %	14.2	9.0	19.8	27.1	<0.001	<0.001	0.042
- ACE inhibitors or ARBs, %	28.1	19.1	35.9	54.2	<0.001	<0.001	<0.001
<b>Sample restricted to hypertensive subjects</b>	<b>(n=543)</b>	<b>(n=207)</b>	<b>(n=207)</b>	<b>(n=129)</b>			
Antihypertensive treatment with:							
- ACE inhibitors, %	46.2	51.7	42.5	43.4	0.061	0.14	0.9
- ARBs, %	42.0	41.6	43.5	40.3	0.7	0.8	0.6
- ACE inhibitors or ARBs, %	82.9	88.4	78.7	80.6	0.008	0.049	0.7

130 <sup>A</sup> Mild versus severe subjects. <sup>B</sup> Mild versus very severe subjects; <sup>C</sup> Severe versus very severe subjects. <sup>D</sup> Congestive heart failure, myocardial infarction, or stroke. COPD = Chronic  
 131 obstructive pulmonary diseases. ACE = Angiotensin-Converting Enzyme. ARBs = Angiotensin II Receptor Blockers.

132

133 **Figure 1. Treatment with ARBs or ACE inhibitors by COVID-19 severity among hypertensive subjects**  
 134 **(horizontal bars are referred to 95% Confidence Intervals).**

135

136 In multivariable analyses restricted to hypertensive subjects (Models A and B, Table 2), the treatment with  
 137 ARBs and/or ACE inhibitors never increased the likelihood of severe or very severe/lethal disease (all  
 138  $p > 0.4$ ).

139 **Table 2. Logistic regression model predicting severe or very severe/lethal COVID-19 syndrome (grouped**  
 140 **together, Model A) or very severe/lethal disease only (Model B), in the sample restricted to hypertensive**  
 141 **subjects.**

	(A) Severe or very severe/lethal OR (95% CI)	p*	(B) Very severe/lethal OR (95% CI)	p*
Antihypertensive drugs:				
- ACE Inhibitors	0.70 (0.44-1.13)	0.15	0.82 (0.49-1.36)	0.4
- ARBs	0.91 (0.56-1.47)	0.7	0.83 (0.50-1.40)	0.5
- ACE Inhibitors or ARBs *	0.58 (0.34-1.01)	0.056	0.87 (0.50-1.49)	0.6

142 ACE = Angiotensin-Converting Enzyme. ARBs = Angiotensin II Receptor Blockers. OR = odds ratio. CI = Confidence interval.

143 All estimates have been adjusted for age, gender, diabetes, major cardiovascular diseases, COPD, cancer and renal diseases.

144 \* Models A and B have been repeated including ACE or ARBs treatment, grouped, with no substantial changes for other  
 145 independent variables.

146

147 The significant predictors of severe disease were male gender (Adjusted Odds Ratio - AOR: 1.76; 95%  
 148 Confidence Interval - CI: 1.40-2.23), diabetes (AOR: 1.52; 1.05-2.18), CVD (AOR: 1.88; 1.32-2.70) and  
 149 COPD (1.88; 1.11-3.20), and older age, which showed an exponential increase after 70 years: compared with  
 150 the subjects younger than 50 years, the AORs of those aged 70-79 and  $\geq 80$  years were 5.72 (3.81-8.58) and  
 151 9.06 (6.04-13.6), respectively (Model C; Table 3). Only male gender, older age and diabetes also predicted  
 152 very severe/lethal disease (Model D; Table 3).

153 **Table 3. Logistic regression model predicting severe or very severe/lethal COVID-19 syndrome (grouped**  
 154 **together, Model C) or very severe/lethal disease only (Model D), in the total sample (n=1603).**

Variables	(C) Severe or very severe/lethal OR (95% CI)	p*	(D) Very severe/lethal OR (95% CI)	p*
Male gender	1.76 (1.40-2.23)	<0.001	1.69 (1.20-2.37)	0.003
Age class, in years				
- <50 (Ref. cat.)	1	--	1	--
- 50-59.9	2.36 (1.68-3.32)	<0.001	3.92 (1.48-10.3)	0.006
- 60-69.9	3.51 (2.43-5.07)	<0.001	11.4 (4.63-28.1)	<0.001
- 70-79.9	5.72 (3.81-8.58)	<0.001	16.5 (6.66-40.9)	<0.001
- ≥80	9.06 (6.04-13.6)	<0.001	27.1 (11.1-66.3)	<0.001
Diabetes	1.52 (1.05-2.18)	0.025	1.58 (1.06-2.34)	0.023
Hypertension	1.10 (0.82-1.47)	0.5	1.39 (0.94-2.05)	0.097
Major cardiovascular diseases **	1.88 (1.32-2.70)	0.001	1.05 (0.71-1.56)	0.8
Cancer	1.26 (0.81-1.95)	0.3	1.11 (0.67-1.82)	0.7
COPD	1.88 (1.11-3.20)	0.020	1.44 (0.84-2.47)	0.2
Renal disease	1.58 (0.90-2.76)	0.11	1.13 (0.64-1.99)	0.7

155 COPD = Chronic obstructive pulmonary diseases. OR = odds ratio. CI = Confidence interval. ACE = Angiotensin-Converting  
 156 Enzyme. ARBs = Angiotensin II Receptor Blockers.

157 \* Treatments with ACE inhibitors and ARBs have not been included in both models because of multicollinearity with  
 158 hypertension. \*\* Heart failure, myocardial infarction, or stroke.

159

## 160 Discussion

161 The main findings of this retrospective, observational study, are the following: first, it is confirmed that,  
 162 among hypertensive subjects, the use of ACE inhibitors or ARBs up to two years preceding SARS-CoV-2  
 163 infection did not affect the severity of COVID-19. Second, older age, male gender, diabetes, and the  
 164 presence of COPD or CVD were independent predictors of severe disease, with a sharp increase of risk  
 165 among subjects older than 70 years. Third, only older age, male gender and diabetes were associated with a  
 166 higher likelihood of very severe/lethal disease.

167 Several hypotheses have been made on the association between COVID-19 progression and treatment with  
 168 ACE inhibitors and ARBs [8-10, 20, 21]. On one side, some asked whether the therapy should be  
 169 discontinued during SARS-Cov-2 pandemic [7, 22] because of a strong association between hypertension

170 and disease severity (although the pharmacological treatment were not assessed) [2-4], and based on the  
171 hypothesis that: (a) ACE2 up-regulation mediated by ARBs (and, to a lesser extent, by ACE inhibitors)  
172 might increase patients' susceptibility to SARS-CoV-2 entry into host cells and further viral propagation  
173 [20], (b) virus binding to ACE2 might reduce its activity, thus leading to increased levels of Angiotensin II  
174 and consequent pulmonary vasoconstriction, inflammation and oxidative organ damage, and increased risk  
175 of acute lung injury [8]. On the opposite side, other scientists suggested that, other than being harmful, ARBs  
176 and ACE inhibitors use in patients with cardiovascular risk factors and known or suspected COVID-19 may  
177 even exert a beneficial effect, as ACE2 up-regulation could increase the conversion of Angiotensin II to  
178 Angiotensin-(1-7), a peptide with potentially protective anti-inflammatory properties [20, 21].

179 Recently, three large observational studies based upon inpatient only [14] or in- and outpatient electronic  
180 health records [15, 16] examined the association between antihypertensive medications and the risk of  
181 COVID-19 and/or a severe/lethal disease: our results substantially confirm these previous findings and,  
182 concordantly, no increased risk emerged with ACE inhibitors and/or ARBs use. Of note, Mehra et al [14],  
183 after controlling for age, gender, current smoke and comorbidities, found similar death rates among COVID-  
184 19 patients using ARBs, and even lower death rates among ACE inhibitors users. The latter results, however  
185 - although in line with a previous observational analysis on Chinese in-hospital COVID-19 subjects [12], are  
186 based upon hospitalized patients only, may be due to unmeasured confounding and, in the absence of  
187 randomized evidence, should be considered only preliminary [23].

188 Our study, likewise Mancina et al [15] and Reynolds et al [16], included all infected subjects (either  
189 hospitalized or not), retrieved all medications and admissions from electronic health records, and evaluated  
190 the disease progression beyond mortality. Concordantly, all these findings confirm those from preliminary  
191 Chinese cohorts [12, 19] and strongly support the statements of several experts [24, 25] and scientific  
192 societies, including the European Medicines Agency [26], the European Society of Cardiology [27], and the  
193 American Heart Association [28], who recommend continuation of ARBs or ACE inhibitors medication for  
194 all patients, unless otherwise advised by their physicians.

195 With regard to the role of the other risk factors that have been suggested for severe COVID-19, including  
196 age, male gender, hypertension, diabetes, COPD, and major cardiovascular diseases, it has been correctly  
197 argued that, so far, available data were unadjusted, thus the relative importance of underlying health

198 conditions was unclear [9, 17]. In this study, we found support for a potential role of gender, diabetes, COPD  
199 and CVD, beyond age, in COVID-19 progression to a severe disease, whereas only gender and diabetes  
200 significantly increased the risk of a lethal or very severe outcome. Thus, the present study confirms prior  
201 findings on the independent relationship of older age and male gender with death [14], and of COPD with  
202 progression towards severe disease [15]. Instead, at least two issues may have influenced the conflicting  
203 results on the role of CVD and COPD in predicting very severe/lethal disease (an association showed in  
204 some prior populations [14] - but lacking in the present as well as in other recent findings [15]): first, the  
205 relatively small sample of the present study; second, a marked difference in the population here enrolled, as  
206 compared to previous studies which included randomly selected SARS-CoV2 negative subjects as controls  
207 [15], or hospitalized-only patients [14]. Given the present scenario, further population-based cohort studies,  
208 with longer follow-up are clearly needed [17] to clarify these findings.

209 In addition to a relatively small sample, another limitation of the present study is the lack of tobacco smoking  
210 and body mass index among the variables that have been recorded, because we could not extract such  
211 information for half of the deceased subjects, as well as for many of those that were not hospitalized.

212 In conclusions, the present study did not find any association between COVID-19 severity and treatment  
213 with ARBs, ACE inhibitors, or both, and confirms previous findings in supporting the recommendation of  
214 several scientific societies to continue ARBs or ACE inhibitors medication for all patients, unless otherwise  
215 advised by their physicians, who should thus be reassured. The adjusted analyses substantially confirm prior  
216 reports, indicating that the risk of severe or lethal COVID-19 largely and significantly increases among the  
217 elderly, males, diabetics, and those with COPD or major cardiovascular diseases.

218

219 **Conflicts of interest:** None declared.

220

221 **Authors' contribution:** Conceptualization, F.B., M.E.F., T.C. and La.M.; methodology, C.A.V., G.C.,  
222 A.D.T., C.A.M., G.P., Lo.M., M.E.F. and La.M.; validation, T.C., G.P., Lo.M., C.A.V., and L.M.; formal  
223 analysis, F.B., C.A.M., M.E.F. and La.M.; investigation, C.A.V., G.C., A.D.T., G.P., and C.A.M.; data  
224 curation, F.B., M.E.F., and La.M.; writing—original draft preparation, M.E.F. and La.M.; writing—review  
225 and editing, F.B., T.C., C.A.V., G.C., A.D.T., G.P., Lo.M.; supervision, T.C. and La.M.; project  
226 administration, F.B. and T.C. All authors have read and agreed to the published version of the manuscript.  
227 La.M. takes responsibility for the integrity of the work as a whole.

228

229 **Access to data:** The complete dataset used in this work is available in Appendix S1.

## 230 **References**

- 231 1. COVID-19 Coronavirus Outbreak [Internet]. Dadax. 2020 [cited March 14, 2020]. Available from:  
232 <https://www.worldometers.info/coronavirus/>.
- 233 2. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients  
234 with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.  
235 *Lancet Respir Med*. 2020. Epub 2020/02/28. doi: S2213-2600(20)30079-5 [pii]  
236 10.1016/S2213-2600(20)30079-5. PubMed PMID: 32105632.
- 237 3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus  
238 Disease 2019 in China. *The New England journal of medicine*. 2020. Epub 2020/02/29. doi:  
239 10.1056/NEJMoa2002032. PubMed PMID: 32109013.
- 240 4. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140  
241 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020. Epub 2020/02/23. doi:  
242 10.1111/all.14238. PubMed PMID: 32077115.
- 243 5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from  
244 Wuhan: An analysis based on decade-long structural studies of SARS. *J Virol*. 2020. Epub 2020/01/31. doi:  
245 JVI.00127-20 [pii]  
246 10.1128/JVI.00127-20. PubMed PMID: 31996437.
- 247 6. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: Physiological  
248 relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. *Pharmacol Res*.  
249 2017;125(Pt A):21-38. Epub 2017/06/18. doi: S1043-6618(17)30178-0 [pii]  
250 10.1016/j.phrs.2017.06.005. PubMed PMID: 28619367; PubMed Central PMCID: PMC5607101.
- 251 7. Fang I, Karakiulakis, G., Roth, M. . Are patients with hypertension and diabetes mellitus at increased  
252 risk for COVID-19 infection? *Lancet Respir Med*. 2020;[epub ahead of print]. Epub March, 11, 2020. doi:  
253 <https://doi.org/10.1016/PIL>.
- 254 8. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin  
255 Angiotensin System Blockers. *JAMA Cardiol*. 2020. Epub 2020/04/04. doi: 10.1001/jamacardio.2020.1282.  
256 PubMed PMID: 32242890.
- 257 9. Patel AB, Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin  
258 Receptor Blockers: What Is the Evidence? *JAMA*. 2020. Epub 2020/03/26. doi: 10.1001/jama.2020.4812.  
259 PubMed PMID: 32208485.
- 260 10. Aronson JK, Ferner RE. Drugs and the renin-angiotensin system in covid-19. *BMJ*.  
261 2020;369:m1313. Epub 2020/04/04. doi: 10.1136/bmj.m1313. PubMed PMID: 32241880.
- 262 11. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-  
263 Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *The New England journal of*  
264 *medicine*. 2020. Epub 2020/04/01. doi: 10.1056/NEJMSr2005760. PubMed PMID: 32227760; PubMed  
265 Central PMCID: PMC7121452.

- 266 12. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of Inpatient Use of Angiotensin  
267 Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With  
268 Hypertension Hospitalized With COVID-19. *Circ Res.* 2020. Epub 2020/04/18. doi:  
269 10.1161/CIRCRESAHA.120.317134. PubMed PMID: 32302265.
- 270 13. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With  
271 Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019  
272 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol.* 2020. Epub 2020/04/24. doi:  
273 10.1001/jamacardio.2020.1624. PubMed PMID: 32324209.
- 274 14. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and  
275 Mortality in Covid-19. *N Engl J Med.* 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2007621. PubMed  
276 PMID: 32356626.
- 277 15. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System  
278 Blockers and the Risk of Covid-19. *N Engl J Med.* 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2006923.  
279 PubMed PMID: 32356627.
- 280 16. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-Angiotensin-  
281 Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med.* 2020. Epub 2020/05/02. doi:  
282 10.1056/NEJMoa2008975. PubMed PMID: 32356628.
- 283 17. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. *BMJ.*  
284 2020;368:m1198. Epub 2020/03/29. doi: 10.1136/bmj.m1198. PubMed PMID: 32217618.
- 285 18. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in  
286 Relation to COVID-19 in Italy. *JAMA.* 2020. Epub 2020/03/24. doi: 10.1001/jama.2020.4683  
287 2763667 [pii]. PubMed PMID: 32203977.
- 288 19. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment  
289 Coronavirus (COVID-19). 2020. Epub 2020/03/10. doi: NBK554776 [bookaccession]. PubMed PMID:  
290 32150360.
- 291 20. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-  
292 Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med.* 2020. Epub  
293 2020/04/01. doi: 10.1056/NEJMsr2005760. PubMed PMID: 32227760; PubMed Central PMCID:  
294 PMC7121452.
- 295 21. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19  
296 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. *Hypertension.*  
297 2020:HYPERTENSIONAHA12015082. Epub 2020/03/27. doi: 10.1161/HYPERTENSIONAHA.120.15082.  
298 PubMed PMID: 32208987.
- 299 22. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol.*  
300 2020;17(5):259-60. Epub 2020/03/07. doi: 10.1038/s41569-020-0360-5  
301 10.1038/s41569-020-0360-5 [pii]. PubMed PMID: 32139904.

- 302 23. Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino RB, Sr., Harrington DP. Inhibitors of the Renin-  
303 Angiotensin-Aldosterone System and Covid-19. *N Engl J Med*. 2020. Epub 2020/05/02. doi:  
304 10.1056/NEJMe2012924. PubMed PMID: 32356625.
- 305 24. Kuster GM, Osswald S. Switching antihypertensive therapy in times of COVID-19: why we should  
306 wait for the evidence. *European heart journal*. 2020. Epub 2020/04/24. doi: 10.1093/eurheartj/ehaa335.  
307 PubMed PMID: 32324223.
- 308 25. Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P, et al. SARS-CoV2: should  
309 inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? *European heart journal*.  
310 2020. Epub 2020/03/21. doi: 10.1093/eurheartj/ehaa235. PubMed PMID: 32196087.
- 311 26. European Medicines A. EMA advises continued use of medicines for hypertension, heart or kidney  
312 disease during COVID-19 pandemic2020 April 20, 2020. Available from:  
313 [https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-](https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic)  
314 [disease-during-covid-19-pandemic](https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic).
- 315 27. European Society of C. Position statement of the ESC Council on Hypertension on ACE-inhibitors  
316 and angiotensin receptor blockers.2020 April 20, 2020. Available from:  
317 [https://www.escardio.org/Councils/Council-on-Hypertension-\(CHT\)/News/position-statement-of-the-esc-](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang)  
318 [council-on-hypertension-on-ace-inhibitors-and-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang).
- 319 28. American Hearth A. Patients taking ACE-i and ARBs who contract COVID-19 should continue  
320 treatment, unless otherwise advised by their physician2020. Available from:  
321 [https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-](https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician?utm_campaign=sciencenews19-)  
322 [treatment-unless-otherwise-advised-by-their-physician?utm\\_campaign=sciencenews19-](https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician?utm_campaign=sciencenews19-)  
323 [20&utm\\_source=science-news&utm\\_medium=phd-link&utm\\_content=phd03-17-20](https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician?utm_campaign=sciencenews19-20&utm_source=science-news&utm_medium=phd-link&utm_content=phd03-17-20).  
324

